The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells von Joly, S, Porcherot, M, Radreau, P, Vonderscher, J, André, P, Meldrum, E, Arold, G, Van de Wetering de Rooij, J, Staner, C, Laveille, C, Scalfaro, P

Volltext

Predictive in vitro models of in vivo cataract formation by an H3-receptor antagonist von Momburg, Ralph, Maisonneuve, Catherine, Bertheux, Hélène, Bazot, Dominique, de Sousa, Elvira, Delongeas, Jean-Luc, Claude, Nancy, Wormstone, Michael, Sanderson, Julie, Radreau, P., Rhodes, J.

Volltext

SAT-158 - The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells von Joly, S., Porcherot, M., Radreau, P., Vonderscher, J., André, P., Meldrum, E., Arold, G., Van de Wetering de Rooij, J., Staner, C., Laveille, C., Scalfaro, P.

Volltext

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis of proteins in dry-cured hams: Data registration and multivariate analysis across multiple gels von Olias, Raquel, Maldonado, Barbara, Radreau, Pauline, Le Gall, Gwénaëlle, Mulholland, Francis, Colquhoun, Ian J., Kemsley, E. Katherine

Volltext

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study von Erken, R., Andre, P., Roy, E., Kootstra, N., Barzic, N., Girma, H., Laveille, C., Radreau-Pierini, P., Darteil, R., Vonderscher, J., Scalfaro, P., Tangkijvanich, P., Flisiak, R., Reesink, H.

Volltext bestellen